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ABSTRACT
Computational Molecular Docking Models and Design of Diarylpentanoids for the
Androgen Receptor
by Jarett A. Guillow
The androgen receptor (AR) is a member of the nuclear receptor protein family that, upon binding
to its natural ligand dihydrotestosterone (DHT) in the cytoplasm, translocates to the nucleus and
exerts nuclear transcription factor activity to drive gene expression related to normal prostate
development. AR signaling becomes overactive during the development and progression of
prostate cancer through different mechanisms, including over-expression and mutation of the AR.
Therefore, the AR is a prominent molecular target in the clinical management of prostate cancer.
However, all therapeutic modalities targeting the AR, including androgen ablation therapy and AR
block suffer from transient efficacy and invariably lead towards resistance and more aggressive,
metastatic disease. Therefore, it is imperative to develop new therapeutic approaches. ca27 is a
diarylpentanoid organic small molecule analog of the natural product curcumin that was previously
shown to down-regulate the expression of the AR and to induce prostate cancer cell death. While
its mechanism of action remains unknown, we hypothesized a potential physical interaction with
the AR, leading to its degradation. In this research, we analyzed the AR in the DBD and LBD both
in binding pockets and in the entire domain. The results indicate negligible binding to the DBD
and positive binding in both binding models of the LBD. Further analysis of the models indicates
the presence of a new binding pocket, hereby referred to as the ca27 binding pocket, in the LBD
where ca27 and its various analogs bind in non-competition to the natural DHT ligand. These
results were developed in MolSoft ICM Pro and further verified by AutoDock through 1-Click

Docking. Further research into designing new ligands was performed however the results were
inconclusive and needs further study.
Keywords: Androgen Receptor, dihydrotestosterone, prostate cancer, ca27, curcumin,
diarylpentanoid, MolSoft, AutoDock, ligand binding domain, DNA binding domain.
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1 Introduction
The androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the DNA binding domain (DBD), the ligand
binding domain (LBD), the hinge region, and the N-terminal domain1 (Figure 1).

Figure 1: Protein / gene organization of the androgen receptor (AR). The AR gene is located on
the X chromosome and is 919 base pairs long. It consists of 8 exons that translates into a protein
of 110 kDa. There are 4 distinctive domains: The N-terminal domain (NTD), which contains
typical poly-glutamine stretches, a DNA binding domain (DBD), a hinge region, and a Cterminal ligand binding domain (LBD).2
AR activity is upregulated in a variety of different cancer types. In breast cancer, approximately
60-80% of patients showed this up-regulation3 and in pancreatic cancer, the survival rates of those
found to have up-regulation in the AR pathway was almost 0% for one year4. Most notable
however is the AR’s role in prostate cancer, where approximately 50% of the patients studied
showed up-regulation or mutations in this pathway5. Prostate cancer is the most common cancer
in men and the second leading cause of death for any form of cancer6. After progression of the
cancer, the tumor enters a new phase in which the prostate cells employ multiple self-defense
mechanisms that allow it to survive in a low androgen environment7. Evidence now suggests that
both residual androgens and the AR play a key role to the progression of the disease to these
stages8. The human AR is a common target for treatment of prostate cancer growth. In the 1940s,
Charles Huggins was the first to discover that androgen ablation therapy was a successful treatment
1

for patients with metastatic prostate cancer1. This was based off increasing evidence that the AR
activity persists even in patients with the castration-resistant form of prostate cancer, leading to
the belief that the AR is a valid drug target for all stages of the disease9. Treatments of prostate
cancer focusing on the AR have become common. An emerging area of focus is the usage of
curcumin and various analogs to chemically target the AR in prostate cancer patients. The natural
product curcumin and its analogs have been found to show potent antioxidant activity10, antiinflammatory activity11, cytotoxicity against tumor cells12, and anti-tumor-promoting
activities13,14. The multitude of beneficial activities of curcumin and its pharmacologically safe
profile, together with its well-known limitations with respect to bioavailability, lead to many
structure activity relationship (SAR) studies using de novo synthesized analogs15. A special group
of synthetic analogs of curcumin are the diarylpentanoids that seem to show an elevated anti-tumor
and oxidant effect in several cell models16,17. In 2006, Weber et al introduced a series of
diarylpentanoid analogs with inhibitory effect for the nuclear factor kappa B (NFκB)18. Among
these compounds was curcumin analog ca27.
ca27 was studied further and found to down-regulate the AR protein expression in human
prostate cancer cell models, including LNCaP and LAPC4, as well as led to the rapid induction of
reactive oxygen species (ROS)19 (see below). These findings marked ca27 as a potential lead
compound for the development of therapeutic compounds for prostate cancer. However, these
studies did not identify the exact mechanism of action (MOA) of ca27. The latter remains to date
a substantial gap of knowledge and warrants further investigations, which is the very essence of
this research.

2

2

2.1

Previous Studies and Review of
Literature
ca27 and the Androgen Receptor

The AR is activated by testosterone (T), which is converted intracellularly by the enzyme 5αreductase to dihydrotestosterone (DHT). DHT is the strongest natural ligand of the AR and induces
its translocation to the nucleus, where it acts as a transcription factor, promoting pro-proliferative
and pro-survival gene expression (Figure 2).

Figure 2: Signaling pathway of the androgen receptor (AR). Testosterone (T) bound to sex
hormone binding protein (SHB) enters the cell and is converted by 5α-reductase to
dihydrotestosterone (DHT). DHT dislocates heat shock binding protein 90 (HSP90) from the AR
and binds it with high affinity. AR dimerizes and becomes phosphorylated (P), then translocates
3

to the nucleus where it recognizes promoter regions containing androgen responsive elements.
Upon recruiting several Co-regulators (Co-Reg) and the general transcription apparatus (GTA),
it induces the transcription of pro-proliferative and pro-survival genes, as well as the biomarker
prostate specific antigen (PSA).
Previous research19,20 has found that a mutated AR is constitutively active as a transcription factor
in LNCaP, thereby perpetually promoting the above traits. This makes LNCaP cells highly
cancerous. As mentioned above, ca27 down-regulates the expression of the AR in LNCaP cells
(Figure 3). This leads to growth inhibition and cell death20. ca27 features α-β-unsaturated carbon
bonds (commonly referred to as Michael acceptors) and aromatic rings as well as ortho- positioned
hydroxyl (OH) groups on the aromatic rings. Structurally diverse analogs of ca27 (see below) also
show the ability to down-regulate the expression of the AR, but with different efficiencies.

Figure 3: The diarylpentanoid ca27 down-regulates the expression of the mutated AR in LNCaP
human prostate cancer cells at low micromolecular concentrations. Protein expression is shown
by Western blot and quantification normalized to the housekeeping gene β-actin20.
The different analogs of ca27 under investigation are all diarylpentanoids, however, they differ in
regard to their hydroxyl group positioning or lack of hydroxyl groups on the aryl rings. Other
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analogs differ in the presence or absence of the α-β-unsaturated carbon bonds (Michael acceptors)
on the carbon chain. Some of the ca27 analogs under investigation are shown in Figure 4.

Figure 4: The diarylpentanoid ca27 and its structural analogs CA58 (meta-positioned hydroxyl
[OH] groups), CA51 (para-positioned OH groups), ca27 MA- (lacking the Michael acceptors),
and ca27 OH- (lacking the OH groups). Right bottom: The natural product curcumin with its
functional groups.
While the Michael acceptors and the hydroxyl groups are hypothesized to be essential to the antiAR expression effectiveness of ca27, its exact mechanism(s) of action remain unknown. However,
it is not inconceivable that ca27 and its analogs physically interact with the AR, thereby inducing

5

its down regulation. The present research project explored this possibility, as outlined further in
the hypothesis (see below).

2.2

Computational Modeling of Curcumin and the AR

Previous studies have used computational modeling to study a possible interaction between
curcumin and curcumin analogs, and the AR. Of note, one study focused on contour maps
generated by binding a variety of analogs of curcumin to the AR21. In this research, the
investigators used three-dimensional quantitative structure activity relationships (SAR) software
(3D-QSAR), SYBYL X 1.3 (Tripos Associates Inc., St. Louis, Missouri, USA, 2011), comparative
molecular field analysis (CoMFA), and comparative similarity indices analysis (CoMSIA) to
produce statistically significant results utilizing 40 different analogs of curcumin. After analysis
using contour maps, the most active compound (compound 29) was used in further in-depth
docking analysis to view the geometric interactions with the AR. After further studying compound
29 and comparing the residual groups of each compound analyzed, a new group of 30 different
analogs were derived that have the potential to be more active compounds than those initially
studied, and their possible binding affinities and activity levels were hypothesized using their
predicted pIC50 values21.
Another study focused on SAR studies of 44 different analogs of curcumin and then used SYBYL
6.0 to further analyze target compounds classified to be a new class of antiandrogen agents22. Of
these 44 compounds, the 5 determined to have antiandrogen effects were dimethylated curcumin
(4), bis(methoxycarbonylmethyl) ether (20), ethoxycarbonylethyl (22), compound 23, and 1,3bis(3,4-dimethoyxphenyl)-1,3-propandione (39). The isolation of these 5 compounds led to an
understanding through the SAR studies that bis(3,4-dimethoxyphenyl) moieties, a conjugated #-
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diketone, and an ethoxycarbonylethyl group at the C-4 position, play important roles in creating
the antiandrogen effects. These findings may be important for future antiandrogen agents and will
lead to further research and understanding as to what structures and substituents are pertinent to
down regulating the expression of the AR22.
One last study of note utilized previous computational studies as well their own analysis in order
to determined that a chemical compound with two bulky side chains would be effective in prostate
cancer cell treatment and would down-regulate the expression of the AR23. The investigators
found that they could obtain such compounds by incorporating two dietary agents, #-ionone and
curcumin, into one chemical entity. Eleven compounds were synthesized based off this concept
and of them, one compound (compound 6) showed low micro molar cytotoxicity and potentially
suppressed DHT-induced transactivation of the AR in prostate cancer cells. Through molecular
docking modeling analysis, compound 6 was found to bind to the LBD of the AR at the hormone
(DHT) binding pocket23. These results need to be corroborated with our research as this previous
project was completed utilizing now outdated and possibly unreliable software.
Utilizing these previous studies as partial guides, a template approach was designed which guided
this research, which is focused on the generation of new computational docking models of the
potential binding of ca27 and its analogs to the AR.

2.3

Previous MolSoft ICM Results from Undergraduate Senior Capstone

Molecular docking modeling of ca27 and its analogs has already been attempted as a senior
undergraduate biochemistry capstone project. During this research, ca27 and multiple different
analogs were bonded to both the LBD and the DBD of the AR and their respective binding
affinities were compared to the natural ligands to determine the favorability of the analogs.

7

Figure 5: All different ligands bonded to the LBD of the AR. A) depicts ca27, B) depicts ca58, C)
depicts ca51, D) depicts ca27 without hydroxyl groups, E) depicts ca27 with the Michael
acceptors, and F) depicts the negative control docetaxel.
The first binding attempt was done in the LBD, which was hypothesized to be the favorable
binding domain based off previous biochemical assays and studies. In this experiment, the LBD
was defined by the pre-existing ligand DHT by examining possible sources of interactions between
the receptor and the ligand. DHT was then removed from the complex and was in turn replaced
with ca27 and its various analogs. The LBD showed favorable binding for all the different analogs
with a variety of different affinities with the positive control of DHT and the negative control of
docetaxel indicating normalized scenarios. Figure 5 shows the different ligands bounded to the
LBD (inside the blue pockets for each image) and figure 6 depicts a quantitative graph of the
favorability of each ligand bonded to the receptor where the more negative score is favorable. The
quantitative graph depicts ca27 to have favorable binding, however, the favorability is not as high
as the natural ligand DHT that would inhibit the binding. However, one of the analogs, ca58,
showed favorable binding near comparable to the natural ligand DHT. This leads ca58 to be the
primary molecule of interest despite its free energy being closer to zero than DHT.
8

Figure 6: A graphical representation of the scores of the different ligands bonded to the
human AR LBD with corresponding scores with a positive control of DHT and a negative
control of docetaxel
The second binding attempt was completed in respects to the DBD. In this domain, because
of the transcriptional function of the DBD, it has no natural ligand. However, pyrvinium pamoate
(PP) has been shown to have a strong binding affinity to the DBD and was used as the positive
control. PP was exposed to the AR and all possible interactions between the two were mapped
and used to define the DBD. The DBD showed similar results as the LBD in regard to the
favorability of the binding for the different ligands. Figure 7 shows the different ligands bounded
to the DBD (inside the blue pockets of each image with an arrow indicating their locations). Figure
8 shows a graphical representation of the favorability of each of the ligands bonded to the AR
DNA interaction sites in which the more negative the score represents the more favorable binding
ligand.

9

Figure 7: All different ligands bonded to the DBD of the AR. A) depicts ca27, B) depicts ca58,
C) depicts ca51, D) depicts CA27 without hydroxyl groups, E) depicts CA27 with the Michael
acceptors, and F) depicts the negative control docetaxel.

Figure 8: A graphical representation of the scores of the different ligands bonded to the
human AR DBD with corresponding scores and a positive control of pyrvinium and a
negative control of docetaxel
The results for the binding attempts of the DBD showed multiple analogs with more favorable
binding than the positive control (PP). ca27, the molecule of interest, had more favorable binding
than PP, which leads to the understanding that ca27 was binding to the DBD during the previous
experiments20. More importantly, ca58 was shown to have even more favorable binding than ca27,
which could be indicative of greater downregulation of the AR expression.

10

Figure 9: A comparison graph of binding scores in the DBD (red) and the LBD (blue).
Analysis of the results for the LBD shows that DHT, the positive control bounds with the highest
affinity. This is important to note because it is also the ligand which, when the AR is mutated,
causes the cell line to become oncogenic. However, further analysis of the results shows the ca58
bonded with better affinity than ca27, the molecule of interest, and had a comparable level of
binding to DHT. This indicates that ca58 is the most favorable molecule to bind to the human AR
LBD possibly due to the chemical effects of its meta-positioned hydroxyl groups. The negative
control of docetaxel had very positive results indicating that the scale of the binding is accurate,
and the results are reliable.
Analysis of the results of the DBD binding demonstrates that the positive control (PP) was not the
most effective binding ligand. Instead, 4 different ligands had binding more preferable than the
positive control and of those, ca58 had the highest binding affinity as well as having binding
affinity near twice as strong as the positive control. The reason ca58 might have the highest affinity
is because of its meta-positioned hydroxyl groups. In each of the images for ca58 (both the LBD
11

and the DBD) the red orbs representing the hydroxyl groups can be seen protruding out of the
binding pockets. It is reasonable to hypothesize that because of the hydroxyl groups outside the
binding pocket, that favorable interactions between these polar molecules and the AR are occurring
which account for the increase in bond affinity. Also, it is important to note that the ca27 analogs
without the Michaels acceptors did not have very favorable binding in comparison to the other
analogs which further strengthens the previously held notions that the reason ca27 was down
regulating the expression of the AR is because of the alpha-beta unsaturated carbon bonds.
Upon further analysis of the DBD images, the four ligands, which have binding affinity higher
than the positive control, are bounded to the opposite side of the DNA from the AR whereas the
positive control bound to the same side as the AR. This might attribute to why these four ligands
had higher binding affinity than the positive control, as the binding location to the DNA might be
independent of the presence of the AR. Further research and experimentation will need to be done
to corroborate this. Other docking models are necessary to test whether a more limited DBD would
produce more accurate results.
Analysis of the graph comparing the LBD to the DBD binding affinities (figure 9) sees an overall
preference to the DBD. It is important to note however that the negative control for the DBD was
not nearly as unfavorable as the negative control for the LBD, however it was still overall
unfavorable with a moderately high positive value. Other negative controls were also used for both
LBD and DBD modeling that were not displayed but showed similar if not the same results as
docetaxel. Since this negative control is still unfavorable, the results should be considered to be
valid and as such, the DBD is the preferred binding site for ca27 and its analogs. This corroborates
previous studies as, even in the presence of DHT, ca27 down regulated the expression of the AR
but these models indicate that DHT will bind over ca27 or any of its analogs to the LBD, leaving
12

the DBD the only alternative for the binding of ca27 or its analogs. These results will either be
corroborated by this research or disproven.

2.4

Pains Molecules and their Significance

A major subject of interest in relation to this study is Pan-Assay Interference Compounds, or
PAINS. Most PAINS act as reactive chemicals rather than discriminatory drugs with a wide variety
of mechanisms of actions24. These compounds produce false positive on different biochemical
assays for three main reasons; they interfere in binding interactions by forming aggregates, they
are very protein-reactive, or they directly interfere in assay signaling25. The aggregate formation
problem can be minimized by including a surfactant in the primary screening protocol. The very
protein reactive compounds can be weeded out beforehand via usage of functional group filters.
The only way to determine if a compound is directly interfering with assay signaling is by testing
each individual compound in appropriately equipped labs. In a typical academic screening library,
it was found the 5-12% of the compounds in these libraries are PAINS. Curcumin, the molecule
our compounds of interest are derived from, is believed to be directly interfering with the assay
signaling24. In a study conducted by Baell et al.25, the structure of curcumin was found to be a
putative PAINS, this is important to note because these molecules are not necessarily PAINS as
the required literature information to verify its promiscuous activity is not yet available. Even if
curcumin is classified as PAINS, that is not indicative that it is impossible for it to interact with a
protein in a specific drug-like way, this needs to be further tested to classify.
For our study, it is essential to note that we are not analyzing curcumin; instead, we are analyzing
ca27 and other analogs of it. Ca27 varies in both inter-aryl carbon-chain length and side groups
from curcumin, marking it as a subject of interest to independently verify whether it is PAINS or
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not. It has also been shown the specific analogs of diarylpentanoids have specific activities and
that only a minor change in their composition modifies, or even abrogates, that activity.
Preliminary qRT-PCR (RNA analysis) and western blotting (protein analysis)20 found that
curcumin (while at lower micromolar concentrations) did not affect the expression of the androgen
level in prostate cancer cells whereas ca27 did show decreased expression of the androgen level
and other analogs of ca27 showed varied outcomes, indicating that there are some interactions
occurring and not simply interfering with the assay signaling. Other SAR studies have shown that
specific diarylpentanoids induce ROS and specific protein degradation depending on their
structure. Finally, cheminformatic analysis of ca27 demonstrates more favorable parameters with
respect to the number of hydrogen bond donors/acceptors, logP, etc. This information taken in
total highlight the probability that ca27 and its analogs are not PAINS molecules and are not simply
directly interfering with the assay signaling. In order to further ensure that PAINS are not a part
of this study, we are also operating under the assumption that there is direct binding between the
compounds and the AR, which would avoid the dilemma of determining whether the compound is
binding to the receptor or interfering with the assay.

2.5

Flexibility in the DBD and LBD

One main concern is the comparison of the rigidity versus flexibility of the receptor model. It is
known that calculations based off a single rigid receptor are inadequate to reproduce the natural
complex geometry of the complex in more than 50% of reported cases26. This leads to a need to
introduce receptor flexibility in both the DBD and the LBD of the model in order to account for
the conformational changes that occur during ligand binding. In order to introduce said flexibility,
the most novel and optimal technique is to represent the receptor flexibility itself as a 4th discrete
dimension of the molecular conformational space by using multiple 3D grids comprised of
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superimposed conformers merged into a single 4D object26. In order to accomplish this goal, there
must be receptor and ligand preparations completed, followed by the docking simulations and the
energy evaluations, all of which can be completed and was completed using MolSoft ICM
software.
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3 Hypothesis
1. We hypothesize that ca27 and its analogs bind directly to the DBD and the LBD of the
AR, which causes a conformational change in the structure of the AR, thereby inducing
its degradation, which manifests itself as the observed down-regulation of its expression.
2. We further hypothesize that the presence/absence and the position of the hydroxyl groups
on the aromatic rings will substantially influence the binding in both domains. Similarly,
we hypothesize that the presence/absence of the alpha-beta unsaturated carbon bonds
(also known as Michael acceptors) will also be essential in determining the binding of
these organic small molecules to the AR.
3. We finally hypothesize that a detailed knowledge of the binding between ca27 and the
AR leads to the identification of new compounds with increased AR binding affinity
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4 Specific Aims
1. To determine the binding affinity of ca27 and its analogs to the LBD and the DBD of the
AR using a computational modelling approach.
•

This will be accomplished using the MolSoft docking/modelling software, which will
determine the geometric and chemical strain for ca27, and its analogs based of the free
energy present in the model (further described in section 6) in order to conclude which
features the best physical binding. The results will be corroborated with another,
independent software, AutoDock. These studies are accompanied by biochemical
experimental approaches (outside of this proposal) that are ongoing in Dr. Bisoffi’s
laboratory.

2. To design 2 new organic small molecule(s) with increased binding affinity. One of
which will be of the same structure as ca27 including the polyphenol rings and the other
will be of any structure simply optimizing the binding affinities.
•

This will be accomplished by using the results from specific aim 1. In particular, details
on structural pharmacophores with elevated binding affinity will be utilized to design de
novo novel molecular organic structures. This information will be included into
AutoDock and MolSoft ICM to then optimize the interactions and output the most
favorable docking model using guidelines specified by the user. These structures will be
synthesized by collaborator and organic chemist, Dr. Justin O’Neill (Schmid College of
Science and Technology, Chapman University).
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5 Significance/Impact
5.1

Short-Term Significance/Impact

This investigation contributes to the current trend to query the binding capacity of potential
modulators, regulators, and inhibitors of nuclear receptors OUTSIDE of the known binding
pockets. This is also an ongoing trend for the AR, as summarized in Elshan et al (2018)27. We
expect our research to contribute to this trend and to identify novel binding sites on two domains
of a rather well-known protein. We expect that this will lead to the identification of structural
groups of organic small molecules that may be the source for the development of novel active
pharmacophores to be tested for their ability to down-regulate AR expression. Hence, the present
work will foster several experimental research avenues, including the chemical synthesis of novel
molecules and their testing in biophysical and biochemical in vitro assays to complement and/or
corroborate the results found herein. This in turn will warrant investigations of the effect of such
novel compounds on AR expression in cell models, notably of human prostate cancer origin. In
the long run, these results will ultimately have potential pre-clinical / clinical significance.

5.2

Pre-Clinical/Clinical Significance

Prostate cancer is the most commonly diagnosed cancer among men and has the 2nd highest cancer
mortality rate in the US. Approximate estimates for the incidence (newly diagnosed cases per year)
and for the mortality (number of deaths per year) are 161,000 and 27,000, respectfully28. Prostate
cancer deaths are almost entirely due to the most lethal form of the disease, which is called
castration resistant prostate cancer, CRPC. As the name implies, CRPC emerges as a resistant form
of prostate cancer after a successful but transient androgen ablation therapy using either androgen
18

synthesis or AR blocking, or both, reagents. Often, CRPC emerges in the bone metastatic setting,
in which the primary tumor has been removed but bone metastatic deposits develop29. Most AR
blockers, including the clinically and widely used bicalutamide and enzalutamide, block the AR
from being activated by its natural ligand DHT, but the effect is transient in nature30. In addition,
these compounds are not designed to down-regulate the expression of the AR, which constitutes a
different mode of action. Since ca27 induces such a down-regulation of the AR, leading to cell
death, it represents a relatively new approach towards a potential therapeutic modality. This
warrants further investigation into its mechanism of action. As outlined in our hypothesis, one
possibility is the direct physical interaction between ca27 and the AR, which could induce its
degradation. Degradation enhancing curcumin analogs have previously been described31 rendering
this pathway a likely mechanism of action for ca27. Should the present study reveal and suggest
an interaction between ca27 and the AR and should in vitro biophysical and biochemical tests
corroborate such findings, this will warrant the planning and execution of pre-clinical studies
utilizing animal models of prostate cancer.
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6 Materials and Methods/Experimental
Approach
Two software packages were used to computationally model the interaction between ca27, its
analogs and the AR:
•

MolSoft ICM-Pro (MolSoft LCC, San Diego CA). Chapman University holds an
annually renewed license for use.

•

AutoDock (Scripps Research Institute, La Jolla, CA). AutoDock is a freeware. Used
through a third-party site, 1-Click Docking.

The two software programs were used independently and to the same extent to cross-validate,
i.e., corroborate or disprove the results obtained with the other.
Protein Data Base (PDB) files of the AR ligand-binding domain (LBD; 2AMA) and DNA
binding domain (DBD; 1R4I) are available from the RCSB PDB (Protein Data Bank) at
www.rcsb.org. These files, as well as files for ca27 and its analogs of interest will be imported
into MolSoft and AutoDock. The three-dimensional structures of the AR LBD and AR DBD
are show in Figure 10 (images imported from the RCSB PDB).
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Figure 10: Three-dimensional structure of the androgen receptor ligand binding domain (LBD)
and DNA binding domain (DBD). The arrow in LBD denotes the natural ligand
dihydrotestosterone (DHT). The DNA is indicated below the DBD.
Possible molecular interactions between ca27 and its analogs with the AR will include geometric
(structural) and chemical strain (described in depth below), as well as favorability parameters.
These interactions will be explored in respect to both the LBD and DBD. In regard to the LBD,
the investigations will be performed with and without a focus on the ligand-binding pocket (LPC).
In particular, MolSoft ICM determines possible bindings by assigning a numerical score, which
represents the geometric and chemical strain from the free state of the ligand in the binding
pocket32. The ICM scoring function is weighted according to the following parameters (i) internal
force-field energy of the ligand, (ii) entropy loss of the ligand between bound and unbound states,
(iii) ligand-receptor hydrogen bond interactions, (iv) polar and non-polar solvation energy
differences between bound and unbound states, (v) electrostatic energy, (vi) hydrophobic energy,
and (vii) hydrogen bond donor or acceptor de-solvation. The lower the ICM score, the higher the
chance the ligand will bind32.
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The geometric strain from the free state represents the configuration of the ligand-protein structural
complex, where a favorable (or more negative) results indicates the receptor is actually more
relaxed with the ligand and an unfavorable interaction means there is more strain structural than
the free state. The chemical strain represents favorable or unfavorable interactions between the
amino acids of both the ligand and the receptor (meaning chemical compatibility) where, again,
more negative values represents more favorable interactions than the free state. MolSoft outputs
two major values to be considered, Score and VLS Score. The Score is the strain from the free
state for the protein alone whereas the VLS Score is the Score with the addition of the strain on
the ligand as well. For the purpose of our analysis, we focused on the VLS Score as it is a more
comprehensive model of the results as the strain on the ligand is important to docking. AutoDock
takes a similar approach utilizing a suite of automated docking tools used to predict how small
molecules bind to a receptor, given a three-dimensional structure33. Positive and negative controls
will be used to set relative scoring values in perspective to the determined binding affinity of ca27
and its analogs. For the LBD, the positive control is given by DHT, the natural ligand of the AR.
In addition, clinically used AR blockers with proven affinity for the AR LBD will also be subjected
to computational docking. These include bicalutamide and enzalutamide30. Because of the
transcriptional function of the DBD, it has no natural ligand. However, the anti-helminthic
compound pyrvinium pamoate (PP) has recently been discovered to exert high binding affinity to
the AR DBD34 and will thus be used as a positive control. Negative controls for both the LBD and
the DBD will be compounds that are not linked to the androgen signaling axis, including organic
small molecules from the taxol family of compounds, such as docetaxel.
Finally, using tools primarily in AutoDock (however the results shall be corroborated with the
MolSoft software), I attempted to analyze the results of all the different analogs bound to the ligand
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and utilize the best chemical and geometric structures found during the course of this research in
order to design a new analog that will bind with greater affinity to the AR in either the LBD or the
DBD and will hypothetically down-regulate the expression of the AR more. The primary tool used
to design a new analog will be AutoLigand35. This tool rapidly scans high affinity binding pockets
and outputs the optimal volume, shape and best atom types (carbon, hydrogen, or oxygen) to bind
to a user defined pocket. AutoLigand completes this by creating affinity maps using AutoGrid,
which scans each atom type through the grids and records the affinity at each point. It also
performs flood-fills of the user’s input volume at each point in the grid and saves the 10 best nonoverlapping fills. Finally, the fill volume will migrate throughout the region to a shape and location
with the best binding energy and the lowest volume. This migration shall continue until there are
no points that can be moved in order to produce better results35. The output of these results was
then tested in both MolSoft ICM and AutoDock to determine if the new ligands created are superior
binding partners to the AR than any of the analogs from the start of this project.
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7 Results
7.1

MolSoft ICM-Pro

The outputs for MolSoft are classified into 4 categories; the LBD, the generalized LBD, the
DBD, and the generalized DBD.

7.1.1 LBD – DHT Binding Pocket
The first step is to verify that the binding is occurring in the correct location (aka, to the DHT
binding pocket). Figure 11 shows the original, pre-bound DHT ligand found in the crystal
structure for the 2ama file. This was then superimposed with the same DHT ligand that was

Figure 11: DHT crystal structure and DHT ligand bound to the DHT binding pocket in
the LBD
bounded to the ligand with the software.
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We can see that they are both in the exact same position and orientation which is indicative that
our model is running accurately in relativity to the real-world data already collected.
Table 1 shows the results of the various ligands in the LBD-DHT binding pocket.
Table 1: MolSoft ICM LBD-DHT Binding Pocket Results
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The various ligands are DHT (the positive control as it is the natural ligand for the AR in the
DHT binding pocket), ca27 (our molecule of interest) and its various analogs, docetaxel
(negative control, binds to tubulin which is part of the cytoskeleton), MG132 (another negative
control which binds to the proteasome), and R1881 (a more stable structural analog of DHT used
in lab work). The values of significance are the VLS Scores for DHT (-33.08), ca27 (-18.42),
ca58 (-31.69) and docetaxel (264.1).

Figure 12: Docking Results for the various ligands in LBD-DHT binding pocket. A is
DHT. B is ca27. C is ca51. D is ca58. E is ca27 without MA. F is ca27 with OH groups.
G is Docetaxel. F is MG132.
It is important to note that in the ca27 model, the hydroxyl groups are pointed towards each other.
This is an unfavorable electrical interaction as they are both negatively partially charged.
However, we can then see ca58 and its hydroxyl groups are facing opposite directions. This is a
much more favorable interaction and is the most probable reason as to why ca58 had such a
favorable binding score.
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7.1.2 LBD – Generalized
Table 2 shows the results of the various ligands bound in the LBD without specifications to
binding location.
Table 2: MolSoft ICM LBD-General Results

These are the same ligands that were bound to the previous pocket however this trial tested the
entire ligand binding domain, not just the specific LBD pocket. In this trial, the VLS Scores of
significance were DHT (-31.95), ca27 (-16.36), ca58 (-22.81), and Docetaxel (-3.99).
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Figure 13: Docking Results for the various ligands in general LBD. A is DHT. B is
ca27. C is ca51. D is ca58. E is ca27 without MA. F is ca27 with OH groups. G is
Docetaxel. F is MG132.
When binding to the entire pocket with no specifications, these models are validated by DHT
binding in the exact same location and orientation as the previous model, to the DHT binding
pocket. If DHT did not bind to the DHT binding pocket, the validity of this model would be in
question. However, when binding ca27 and its various analogs, they did not show any binding tot
the DHT binding pocket (outlined in blue). Instead, each of the analogs attempted to bind in a
slightly smaller space very near the DHT binding pocket. Further analysis of this new binding site
identified possible chemical bonds that could occur in the area.
In Figure 14, we view a comparison of the original DHT binding pocket to the new ca27 binding
pocket. We can see that the ca27 binding pocket is slightly smaller in size compared to the DHT
binding pocket, however, it is still within the “drug-like” volume and size defined by the software
to be a valid therapeutic target. This second pocket would cause misfolding within the protein and
lead to cell death which explains the experimental results seen in previous research.
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Figure 14: The new binding pocket (ca27 binding pocket) compared in location, surface
area, and volume to the DHT binding pocket.

Figure 15: Outline of the residues surrounding the new ca27 binding pocket with the
highest probability of interacting with bound ligands.
Above we see the new ca27 binding pocket and all the residues within 5 angstroms of the pocket
with the highest probability of interaction with the bound ligands. In particular, residues Q711
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and R752 are of particular interest because these residues are also found in the DHT binding pocket
but more importantly, research has been conducted on these residues stating that they are hydrogen
donors/acceptors for hydrogen bonding.

7.1.3 DBD – Hypothesized Binding Pocket
When inputting the DBD PDB file (1R4I), there is no ligand bound to the crystal structure. In
order to create the binding pocket to be used in the preliminary trials, all possible electrical and
chemical interactions must be evaluated between the AR and the DNA to make a hypothesized
binding pocket. Table 3 shows the results of the various ligands bound in the DBD with this
hypothesized binding pocket. The ligands used in these models were the same as the LBD
models with the exception of the positive control now being pyrvinium pamoate. This is the
theorized positive control for the DBD as discussed previously. The VLS Scores to note are for
PP (-22.99), ca27 (-29.34), ca58 (-29.36), and docetaxel (-9.042).
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Table 3: MolSoft ICM DBD-Pocket Results

In Figure 16, we can see the various ligands bound to the DBD binding pocket. Analyzing the
positive control (PP), the benzene group is orientated towards the AR and appears to be in close
enough proximity to interact with the residues in the protein. ca27 and its analogs all bound
directly into the binding pocket as that was a requirement for the model, however, they are all
bonding nearer to the DNA and farther away from the AR. This is unlikely to affect the AR
however further modeling needs to be completed. The negative control also showed much better
binding in these models than the LBD, however, the results are not conclusive enough to state that
the negative control is favorably binding and nullifying the model.
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Figure 16: Docking Results for the various ligands in DBD binding pocket. A is PP. B is
ca27. C is ca51. D is ca58. E is ca27 without MA. F is ca27 with OH groups. G is
Docetaxel. F is MG132.

7.1.4 DBD – General
Similar to the process completed for the LBD, new models were developed in the DBD no longer
specifying to bind to the pocket. The same ligands were used, and the results are displayed below
in table 4. The VLS Scores of interest are for PP (-24.85), ca27 (-24.46), ca58 (-36.61), and
docetaxel (-15.72).
Figure 17 contains the various results from the models for the generalized DBD. Overall, the VLS
Scores for the generalized DBD appear more preferable however some concerns are raised during
further analysis. The positive control, PP, appears to be binding farther away from the AR and the
benzene group that was previously in close proximity to the AR is now in the exact opposite
orientation. Similar results are seen in the various analogs of ca27, most of these models showed
improved VLS Scores compared to the previous model (which is logical) however, they all were
binding farther away from the AR. It is possible that the binding of these ligands to DNA causes
a conformational change in the DNA which then affects the AR but based off of our biochemical
understanding of these molecules and this system, it is quite unlikely.
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Table 4: MolSoft ICM DBD-General Results

Figure 17: Docking Results for the various ligands in the general DBD. A is PP. B is
ca27. C is ca51. D is ca58. E is ca27 without MA. F is ca27 with OH groups. G is
Docetaxel. F is MG132.

33

One major concern of these models is the steady improvement of binding affinity for the negative
controls. For the previous model, this improvement was not to the extent to raise a concern, but
now docetaxel has a clearly favorable binding affinity, this leads to questions of the validity of
these DBD models as the negative control is no longer unfavorable.

7.2

AutoDock via 1-Click Docking

Due to multiple technical issues attempting to run AutoDock by itself, 1-Click Docking was used
in its stead. 1-Click Docking was an acceptable substitute for AutoDock as it runs the exact same
functions as AutoDock in a much more user-friendly format. First of all, the ligand had to be
manually drawn as a 2D image and then converted to a 3D Mol file by another freeware called
OpenBabel. This 3D mole file is then converted to a PDBQT file by AutoDockTools. The PDB
file is then uploaded to 1-click Docking by the same AutoDockTools software. Finally, the model
is rendered using AutoDockVina, which is an updated version of AutoDock. As is apparent, this
is a multistep process which is why difficulties arose attempting to use solely AutoDock. However,
since 1-Click Docking used all of the AutoDock functions and softwares, it was a preferable
substitute.

7.2.1 1-Click Docking DHT Binding Pocket
The results from 1-Click Docking are limited in their capabilities as the drawback for a more
user-friendly interface was flexibility in the model. As such, the models rendered were limited
to be in the LBD both centered at the DHT binding pocket and at the ca27 binding pocket. Table
5 highlights the binding affinities for the various ligands. It is important to note that a negative
value is still favorable however the scoring function used is different from MolSoft and as such,
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the scale is not relative between the softwares. AKA, the -9.0 score for DHT in this model is
very favorable.
Table 5: 1-Click Docking Results for the DHT Binding Pocket

Figure 18: Docking Results for the various ligands in the LBD centered at the DHT
binding pocket by 1-Click Docking. A is DHT. B is ca27. C is ca51. D is ca58. E is
ca27 without MA. F is ca27 with OH groups.
Figure 18 display the results from 1-Click docking centered at the DHT binding pocket in the LBD.
The software did not have the same functions as MolSoft to draw the pocket so instead the residues
35

for the DHT binding pocket are labeled. DHT fit very well inside the DHT binding pocket as a
positive control, verifying the accuracy of the models. As seen in both table 5 and figure 18, the
ca27 analogs did not prefer binding to the DHT binding pocket in comparison to DHT, so in a
competitive binding scenario, DHT would not be displaced based upon these results. Also, in
figure 17 it is apparent that most of the ca27 analogs are shifting more towards the left (relatively)
of the DHT binding pocket.

7.2.2 1-Click Docking ca27 Binding Pocket
A new model had to be developed for the new ca27 pocket previously defined in the MolSoft
results. Table 6 displays the binding affinities for this new pocket. In these results, DHT is not
nearly as favorable to bind as compared to the previous model which is logical as it has a tendency
to want to bind to the DHT binding pocket. We also see a notable uptick in the values for most of
the various ca27 analogs. This fact coupled with the knowledge of DHT preferring to bind to the
DHT binding pocket implies that the ca27 analogs will bind to this new ca27 binding pocket when
in the presence of DHT.
Table 6: 1-Click Docking Results for the ca27 Binding Pocket
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Figure 19: Docking Results for the various ligands in the LBD centered at the ca27
binding pocket by 1-Click Docking. A is DHT. B is ca27. C is ca51. D is ca58. E is
ca27 without MA. F is ca27 with OH groups.
Figure 19 contains the various models run in 1-Click Docking centered at the new ca27 binding
pocket. The pocket is outlined by the labeled residues determined during the MolSoft trials. DHT
is seen binding as far away as the software will permit from this pocket whereas most of the ca27
analogs are binding directly into the middle of the pocket, in particular, ca58 is binding extremely
well in orientation to the ca27 binding pocket.

7.3

AutoLigand

AutoLigand was used to design and test a new ligand with minimal specifications to the structure
besides approximate volume and surface area. The stepwise process for AutoLigand was to prep
the ligand binding area for analysis, which needed to be done with DHT. DHT was manually
drawn as a 2-dimensional image and converted to a 3D .mol file then converted to a PDBQT file
to upload to AutoDock by OpenBabel. Then the receptor needed to be configured. The receptor
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was uploaded to AutoDock and manually edited (adding hydrogens, merging non-polar
hydrogens, etc.) to be outputted as a PDBQT file. This PDBQT file was then used to create grid
maps by first preparing gpf files and then outputting glg files to be used for AutoLigand.
Finally, AutoLigand is run using the functions previously discussed and outputs a PDB file of the
best ligand given the minimal specifications.

Figure 20: The outputted ligand from AutoLigand (left) and the binding of this new
ligand to the AR LBD in MolSoft
Figure 20 displays the new ligand outputted by AutoLigand. It is composed of 20 atoms
containing, 1 carbon, 11 oxygens, and 8 hydrogens. When bounded to the AR LBD in MolSoft, it
is apparent that this new ligand, which is more condensed than the previous ligands analyzed, does
not bind to either of the pockets previously discussed. This is further corroborated by 1-Click
Docking in figure 21 as this new ligand did not bind to either the DHT binding pocket nor the ca27
binding pocket when centered at each respectively. This is seen as the yellow highlighted residues
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outline the respective pockets, where the DHT binding pocket is in the foreground and the ca27
binding pocket is in the background.

Figure 21: The new ligand produced by AutoLigand bound in 1-Click Docking centered
at the DHT binding pocket (left) and the ca27 binding pocket (right)

39

8 Discussion/Future Research
The binding of the various ligands to the DBD was very inconclusive. Partially due to the
favorable binding of the negative controls leading towards doubts to the validity of the models.
But also, largely due to the migration of the ligands when given more flexibility. This migration
implies that there is no binding to the AR and that the ligands are binding solely because the
software is requiring them to bind. Further experimentation and models will need to be run to
prove or disprove this understanding. Also, further analysis of chemical characteristics of small
molecules with increased binding affinity to the DBD is needed to corroborate the results of
improbable binding.
The LBD had extremely interesting results. The presence of a new binding pocket had never been
experimentally considered before this research. Fluorescence polarization assays had been run to
determine if DHT is being displaced in the DHT binding pocket by ca27 but preliminary results
from these experiments indicate that there is no displacement. If there is indeed another binding
pocket associated with ca27, this would explain why these experimental results are inconclusive.
The biological implications of this new ca27 binding pocket, especially towards therapeutic
treatments for prostate cancer, are very large as this could be a gateway to new target treatments
of cancer with minimal consequences towards the healthy cells. There are 5 residues in this new
pocket (M745, M749, Q711, R752, and F764) which are also found in the DHT binding pocket.
Q711 and R752 in particular are known to participate in hydrogen bonding with bound ligands.
Further research will need to be conducted into which ligand these residues are bounding with
when both DHT and ca27 are binding, assuming they are binding in their 2 respective pockets.
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Also, further research will need to be conducted on these amino acids to determine which are most
probably to have hydrogen bonding or other interactions with the new ca27 binding pocket. It is
also known that a T877->A877 mutation increases activity of the LBD DHT binding pocket in the
AR and it would be interesting to further analyze mutations such as these in this new binding
pocket to determine if a similar scenario could be developed that could further increase the
effectiveness of therapeutic treatments. These results are then corroborated by 1-Click Docking
and therefore AutoDock by proxy. The 1-Click docking results are not very conclusive on their
own however, combined with the analysis of the MolSoft results, there is a strong probability of a
different pocket in the AR. In reference to the various ligands, ca27 consistently had a strong
binding affinity to the pocket of interest however, ca58 also had a strong binding affinity in many
of the trials run. Both of these molecules will need to be further tested as these computational
models cannot state which will bind better, simply that they both have a strong binding affinity.
Most importantly, testing in biophysical and biochemical in vitro assays are needed to compliment
and/or corroborate these computational models.
Finally, the AutoLigand results, while interesting, are not conclusive. The output of AutoLigand
is not a very conceivable ligand and further studies will need to be conducted on AutoLigand in
an attempt to improve the results and output a conceivable molecule to bind to the LBD of the AR.
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9 Conclusion
In conclusion, the softwares used are a valid method to test new molecules for binding affinity and
assist in new understandings of molecular docking.

The DBD was found to not be a valid drug

target for the various curcumin analogs. Most importantly, the LBD was found to contain 2
different binding pockets, the DHT binding pocket and the new ca27 binding pocket which is
where the curcumin analogs preferred to bind.

Finally, the AutoLigand software did not

successfully produce a valid drug target to be further tested and compared to the current treatment
methods.
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